These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33109196)

  • 1. Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity.
    Wang L; Zhou X; Zou W; Wu Y; Zhao J; Chen X; Zhou GG
    J Nanobiotechnology; 2020 Oct; 18(1):153. PubMed ID: 33109196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity.
    Houdaihed L; Evans JC; Allen C
    Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-mimetic nanoplatforms for targeted cancer drug delivery.
    Vázquez-Ríos AJ; Molina-Crespo Á; Bouzo BL; López-López R; Moreno-Bueno G; de la Fuente M
    J Nanobiotechnology; 2019 Jul; 17(1):85. PubMed ID: 31319859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
    Liang G; Zhu Y; Ali DJ; Tian T; Xu H; Si K; Sun B; Chen B; Xiao Z
    J Nanobiotechnology; 2020 Jan; 18(1):10. PubMed ID: 31918721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles.
    Longatti A; Schindler C; Collinson A; Jenkinson L; Matthews C; Fitzpatrick L; Blundy M; Minter R; Vaughan T; Shaw M; Tigue N
    Nanoscale; 2018 Aug; 10(29):14230-14244. PubMed ID: 30010165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo.
    Kawamoto M; Horibe T; Kohno M; Kawakami K
    Mol Cancer Ther; 2013 Apr; 12(4):384-93. PubMed ID: 23358664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Designed Small Molecule Inhibitor of a Non-Coding RNA Sensitizes HER2 Negative Cancers to Herceptin.
    Costales MG; Hoch DG; Abegg D; Childs-Disney JL; Velagapudi SP; Adibekian A; Disney MD
    J Am Chem Soc; 2019 Feb; 141(7):2960-2974. PubMed ID: 30726072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
    Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
    Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
    Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
    ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Delivery of MicroRNA125a-5p by Engineered Lipid Nanoparticles for the Treatment of HER2 Positive Metastatic Breast Cancer.
    Hayward SL; Francis DM; Kholmatov P; Kidambi S
    J Biomed Nanotechnol; 2016 Mar; 12(3):554-68. PubMed ID: 27280253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.
    Irie H; Ito K; Fujioka Y; Oguchi K; Fujioka A; Hashimoto A; Ohsawa H; Tanaka K; Funabashi K; Araki H; Kawai Y; Shimamura T; Wadhwa R; Ohkubo S; Matsuo K
    Mol Cancer Ther; 2019 Apr; 18(4):733-742. PubMed ID: 30787176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.
    Ciravolo V; Huber V; Ghedini GC; Venturelli E; Bianchi F; Campiglio M; Morelli D; Villa A; Della Mina P; Menard S; Filipazzi P; Rivoltini L; Tagliabue E; Pupa SM
    J Cell Physiol; 2012 Feb; 227(2):658-67. PubMed ID: 21465472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.
    Stevic I; Müller V; Weber K; Fasching PA; Karn T; Marmé F; Schem C; Stickeler E; Denkert C; van Mackelenbergh M; Salat C; Schneeweiss A; Pantel K; Loibl S; Untch M; Schwarzenbach H
    BMC Med; 2018 Oct; 16(1):179. PubMed ID: 30301470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells.
    Yang Z; Tang W; Luo X; Zhang X; Zhang C; Li H; Gao D; Luo H; Jiang Q; Liu J
    J Biomed Nanotechnol; 2015 Aug; 11(8):1401-17. PubMed ID: 26295141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
    Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
    Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
    Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
    Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.